IQM
1.7.2021 13:02:09 CEST | Business Wire | Press release
IQM Quantum Computers (IQM) expands its operations to Spain, creating a subsidiary in Bilbao. This operation has been supported by Basque local administration via Provincial Council of Bizkaia and Bilbao City Hall.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210701005046/en/
With its Spain operations, IQM aims to tap into another hotspot for quantum computing in addition to its Finland and Germany offices. IQM Spain will collaborate closely with the local research community, quantum experts from academia and the industry to build a vibrant Spanish and European quantum ecosystem. IQM with its international partner network will also connect the Spanish quantum ecosystem to the global quantum network.
“QUTIS Center in University of the Basque Country Bilbao has outstanding experience and experts in quantum computation and simulation, quantum control, quantum sensing and other areas. Today’s announcement signals our commitment to accelerate the success of our application-specific quantum computers, and aggressively develop quantum finance offerings for our customers worldwide,” said Jan Goetz, CEO at IQM. “Local Public Administration, via Beaz and Bilbao Ekintza, have been extremely supportive and are committed to attracting best talent and growth companies. We look forward to working with their team to grow our Co-Design offering from Spain and deliver it globally.”
The technical goal for this Spanish subsidiary is to create a quantum finance Co-Design hub that tightens the interaction between hardware and software to solve problems in finance. In particular, IQM Spain will develop an application-specific approach where quantum software integrates closely with a suitably designed quantum hardware with novel quantum architectures. Combined with IQM's hardware experts and go-to market teams in Finland and Germany, IQM will be able to deliver this offering to global customers. This approach accelerates the development of useful quantum solutions for specialized financial applications and will establish Spain and Europe as the leaders for quantum finance.
Last year, IQM had also entered into a research agreement with the University of the Basque Country (UPV/EHU) in Bilbao, a collaboration led by Dr. Jorge Casanova (Ramón y Cajal and Ikerbasque researcher at UPV/EHU) and includes Dr. Mikel Sanz (Ikerbasque Researcher at UPV/EHU) and Prof. Xi Chen (Professor at Shanghai University and Ramon y Cajal researcher at UPV/EHU).
Ms. Olatz Goitia, General Manager of Beaz, said, “We work to turn the territory into an innovation hub of international reference, and to this end, the retention and attraction of talent and entrepreneurship and companies like IQM is key.”
Mr. Javier Garcinuño Zabala, General Manager of Bilbao Ekintza, said, “We’re pleased to see European growth companies like IQM start their Spanish operations in Bilbao. Our BIG Bilbao entrepreneurship centre will support their local operations and Bilbao Ekintza will also collaborate with IQM on joint projects in Bilbao’s strategic economic sectors.”
About Beaz:
Beaz is a public company of the Provincial Council of Bizkaia whose objective is to support companies and entrepreneurs in their efforts to create new projects, innovate and internationalize. A goal that is in line with that of the Regional Department of Economic Promotion, to which Beaz reports directly: to contribute to the growth of economic activity and the creation of qualified employment.
About Bilbao Ekintza:
Bilbao Ekintza is a public company of Bilbao City Hall that develops the municipal powers in the field of economic development, promotion of Bilbao and its events as a tourist destination and business promotion, both from the point of view of the attraction, creation and growth of companies and the improvement of opportunities for access to employment.
https://www.bilbaoekintza.eus/en
About IQM Quantum Computers:
IQM is the European leader in superconducting quantum computers, headquartered in Espoo, Finland. Since its inception in 2018, IQM has grown to 110+ employees and established a subsidiary in Munich, Germany, to lead the Co-Design approach.
IQM delivers on-premises quantum computers for research laboratories and supercomputing centers and provides complete access to its hardware. For industrial customers, IQM delivers quantum advantage through a unique application-specific Co-Design approach.
IQM is building Finland’s first commercial quantum computer with VTT, and an IQM-led consortium was awarded € 12.4 Million in February 2021 to commercialize application-specific quantum processors by the German Ministry of Education and Research.
For more information, visit www.meetiqm.com .
Registered office:
IQM Finland Oy
Keilaranta 19
02150 Espoo
Finland
View source version on businesswire.com: https://www.businesswire.com/news/home/20210701005046/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom